Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Munckhof, W. J.
Right arrow Articles by Turnidge, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munckhof, W. J.
Right arrow Articles by Turnidge, J. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 879-883
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Post-antibiotic growth suppression of linezolid against Gram-positive bacteria

W. J. Munckhofa,*, C. Gilesa and J. D. Turnidgeb

a Department of Infectious Diseases, Infection Control and Sexual Health, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102; b Department of Microbiology and Infectious Diseases, Women's and Children's Hospital, 72 King William Road, North Adelaide, South Australia 5006, Australia

The in vitro post-antibiotic effects (PAEs) of eight different concentrations of linezolid against Gram-positive cocci were investigated and the results analysed using the sigmoid Emax model for mathematically modelling the PAE. Mean maximal linezolid PAEs against strains of Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Enterococcus faecium and Streptococcus pneumoniae were 2.2, 1.8, 2.8, 2.0 and 3.0 h, respectively. Resistance to methicillin (for the staphylococci), vancomycin (for the enterococci) and penicillin (for the pneumococci) had no effect on the duration of the PAE. Results of PAE testing support twice-daily dosing of linezolid in humans.

* Corresponding author. Tel: +61-732-405918; Fax: +61-732-405540; E-mail: wendy_munckhof{at}health.qld.gov.au


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Bernardo, N. Pakulat, S. Fleer, A. Schnaith, O. Utermohlen, O. Krut, S. Muller, and M. Kronke
Subinhibitory Concentrations of Linezolid Reduce Staphylococcus aureus Virulence Factor Expression
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 546 - 555.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.